{
    "clinical_study": {
        "@rank": "148189", 
        "brief_summary": {
            "textblock": "Patients with Grade II and III soft tissue sarcomas of the extremity will be randomized to\n      either receive or not receive radiation therapy following surgery for the removal of the\n      local tumor.  All patients in this protocol will receive adjuvant chemotherapy."
        }, 
        "brief_title": "The Role of Multi-Modality Therapy for the Treatment of High-Grade Soft Tissue Sarcomas of the Extremities", 
        "completion_date": "September 2000", 
        "condition": "Sarcoma", 
        "condition_browse": {
            "mesh_term": "Sarcoma"
        }, 
        "detailed_description": {
            "textblock": "Patients with Grade II and III soft tissue sarcomas of the extremity will be randomized to\n      either receive or not receive radiation therapy following surgery for the removal of the\n      local tumor.  All patients in this protocol will receive adjuvant chemotherapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients must have biopsy-proven soft tissue sarcoma with one of the following diagnoses:\n\n        Liposarcoma (round cell or pleomorphic).\n\n        Fibrosarcoma.\n\n        Malignant fibrous histiocytoma.\n\n        Inflammatory malignant fibrous histiocytoma.\n\n        Myxoid malignant fibrous histiocytoma.\n\n        Malignant giant cell tumor.\n\n        Angiomatoid malignant fibrous histiocytoma.\n\n        Leiomyosarcoma.\n\n        Malignant hemangiopericytoma.\n\n        Rhabdomyosarcoma (embryonal, alveolar, pleomorphic or combined).\n\n        Soft tissue sarcoma resembling Ewing's sarcoma.\n\n        Synovial cell sarcoma.\n\n        Epithelioid sarcoma.\n\n        Clear cell sarcoma.\n\n        Neurofibrosarcoma.\n\n        Epithelioid schwannoma.\n\n        Malignant triton tumor.\n\n        Angiosarcoma.\n\n        Mixed malignant mesenchymoma.\n\n        Alvelar soft part sarcoma.\n\n        Malignant granular cell tumor.\n\n        All lesions must be Grade II or  III.  No patients with Grade I lesions will be\n        acceptable.\n\n        Patients must have undergone a limb-sparing procedure in which all gross tumor has been\n        removed.\n\n        Clinical evaluation must reveal no evidence of metastatic disease either in regional lymph\n        nodes or more distant sites.\n\n        The soft tissue sarcoma must be on the extremity either at or distal to the shoulder joint\n        or at or distal to the hip joint.\n\n        The definitive surgical procedure for a primary lesion or for a recurrence must have been\n        performed no longer than four months from the date of randomization.\n\n        Patients must not have received any prior chemotherapy or radiotherapy for their sarcoma.\n\n        Patients without a history of any other malignant disease except basal cell carcinoma.\n\n        Patients who have not had a serious infection, active bleeding disorders, or concomitant\n        severe disease such as cirrhosis, ischemic heart disease, or evidence of severe impairment\n        of renal function.\n\n        Patients must be above the age of 30 and do not have a diagnosis of embryonal\n        rhabdomyosarcoma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "100", 
        "firstreceived_date": "November 3, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00001188", 
            "org_study_id": "830212", 
            "secondary_id": "83-C-0212"
        }, 
        "intervention": {
            "intervention_name": "radiation therapy following surgery", 
            "intervention_type": "Procedure"
        }, 
        "keyword": [
            "Chemotherapy", 
            "Radiation Therapy", 
            "Sarcoma", 
            "Surgery"
        ], 
        "lastchanged_date": "March 3, 2008", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "National Cancer Institute (NCI)"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "The Role of Multi-Modality Therapy for the Treatment of High-Grade Soft Tissue Sarcomas of the Extremities", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "reference": [
            {
                "PMID": "1122498", 
                "citation": "Suit HD, Russell WO, Martin RG. Sarcoma of soft tissue: clinical and histopathologic parameters and response to treatment. Cancer. 1975 May;35(5):1478-83."
            }, 
            {
                "PMID": "7272893", 
                "citation": "Lindberg RD, Martin RG, Romsdahl MM, Barkley HT Jr. Conservative surgery and postoperative radiotherapy in 300 adults with soft-tissue sarcomas. Cancer. 1981 May 15;47(10):2391-7."
            }, 
            {
                "PMID": "4298242", 
                "citation": "McNeer GP, Cantin J, Chu F, Nickson JJ. Effectiveness of radiation therapy in the management of sarcoma of the soft somatic tissues. Cancer. 1968 Aug;22(2):391-7. No abstract available."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00001188"
        }, 
        "source": "National Institutes of Health Clinical Center (CC)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 1983", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1999"
    }, 
    "geocoordinates": {
        "National Cancer Institute (NCI)": "38.985 -77.095"
    }
}